Tests atebimetinib with chemotherapy in advanced pancreatic cancer
Tests atebimetinib added to chemotherapy in adults with metastatic pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Key facts
- Where
- Abilene, Arlington Heights, Atlanta, Austin, Belleville, Blacksburg, Chicago, Cincinnati, Columbia, Duarte, East Brunswick, Eugene, Fairfax, Fairway, Fort Collins, Germantown, Greenville, Huntsville, Las Vegas, Lone Tree, Madison, Maumee, Miami, Nashville, New York, Newark, Omaha, Peoria, Philadelphia, Phoenix, Pinehurst, Port Saint Lucie, Portland, San Antonio, San Diego, Sarasota, Seattle, Sioux Falls, St. Petersburg, Vancouver, Webster, and West Palm Beach, United StatesSee the 47 sites
- Phase
- Phase 3
Where in United States
- Texas Oncology - West TexasAbilene, United StatesTaking people
- Illinois Cancer SpecialistsArlington Heights, United StatesTaking people
- Piedmont Cancer InstituteAtlanta, United StatesTaking people
- Piedmont HealthcareAtlanta, United StatesTaking people
- Texas Oncology - AustinAustin, United StatesTaking people
- Regional Cancer CareBelleville, United StatesTaking people
- Blue Ridge Cancer CareBlacksburg, United StatesTaking people
- City of HopeChicago, United StatesTaking people
- University of Cincinnati Cancer CenterCincinnati, United StatesTaking people
- Maryland OncologyColumbia, United StatesTaking people
- Missouri Cancer AssociatesColumbia, United StatesTaking people
- City of HopeDuarte, United StatesTaking people
- Astera Cancer CareEast Brunswick, United StatesTaking people
- Willamette Valley Cancer InstituteEugene, United StatesTaking people
- Virginia Cancer SpecialistsFairfax, United StatesTaking people
- University of Kansas Cancer CenterFairway, United StatesTaking people
- Poudre Valley Health Care, IncFort Collins, United StatesTaking people
- West Cancer CenterGermantown, United StatesTaking people
- Prisma HealthGreenville, United StatesTaking people
- Clearview Cancer InstituteHuntsville, United StatesTaking people
- Comprehensive Cancer CentersLas Vegas, United StatesTaking people
- Rocky Mountain Cancer CentersLone Tree, United StatesTaking people
- University of Wisconsin Carbone Cancer CenterMadison, United StatesTaking people
- Taylor Cancer Research CenterMaumee, United StatesTaking people
- Miami Cancer InstituteMiami, United StatesTaking people
- Sarah Cannon Research InstituteNashville, United StatesTaking people
- Tennessee OncologyNashville, United StatesTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
- NYU Langone HealthNew York, United StatesTaking people
- Medical Oncology Hematology ConsultantsNewark, United StatesTaking people
- University of Nebraska Medical CenterOmaha, United StatesTaking people
- OSF Medical CenterPeoria, United StatesTaking people
- Thomas Jefferson UniversityPhiladelphia, United StatesTaking people
- City of HopePhoenix, United StatesTaking people
- FirstHealth of the CarolinasPinehurst, United StatesTaking people
- Hematology - Oncology Associates of the Treasure CoastPort Saint Lucie, United StatesTaking people
- Oregon Health and Science UniversityPortland, United StatesTaking people
- Texas Oncology - San AntonioSan Antonio, United StatesTaking people
- University of California San DiegoSan Diego, United StatesTaking people
- Florida Cancer Specialists - SouthSarasota, United StatesTaking people
- University of Washington Fred Hutchinson Cancer CenterSeattle, United StatesTaking people
- Virginia Mason Medical CenterSeattle, United StatesTaking people
- Avera Cancer Institute- ResearchSioux Falls, United StatesTaking people
- Florida Cancer Specialists - NorthSt. Petersburg, United StatesTaking people
- Northwest Cancer SpecialistsVancouver, United StatesTaking people
- Texas Oncology - Gulf CoastWebster, United StatesTaking people
- Florida Cancer Specialists - EastWest Palm Beach, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Immuneering Corporation
- Trial code
- NCT07562152EU 2026-525617-31-00
- Record updated
- 6 November 2026
- Original description
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.Read full original descriptionShow less
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Inclusion: Must be ≥18 years of age; Must have confirmed diagnosis according to AJCC staging as follows:; Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Participants must be treatment naive as follows:; First-line PDAC participants will have received no previous systemic anti-cancer therapy; Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria; Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values.
Exclusion: Inability to swallow oral medications; Participants with only locally advanced disease; Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma; Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases.